IO Biotech Announced Preliminary Data From A Phase 2 Trial Evaluating IO102-IO103 In Combination With Pembrolizumab
Portfolio Pulse from Benzinga Newsdesk
IO Biotech has announced preliminary data from a Phase 2 trial evaluating IO102-IO103 in combination with Pembrolizumab. The company has not disclosed any specific results yet.
October 23, 2023 | 6:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IO Biotech's announcement of preliminary data from a Phase 2 trial could potentially impact the company's stock. However, without specific results, the impact is uncertain.
Clinical trial results can significantly impact a biotech company's stock. However, without specific results, it's difficult to predict the direction of the impact. Investors will likely be closely watching for further details.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100